ELEiko Lifesciences540204Quarterly results

Board approves Q2 & H1 FY27 results; 50-50 joint venture with Oval Projects Engineering considered and approved

Board meeting held on 05 November 2026: unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026 approved, along with the auditor's limited review report.

By ScoutQuest · Thu 5 Nov 2026, 5:00 PM IST · 3 min read

Total income

Latest 1,794.63; Year ago 1,193.28 (+50.4%); Prev qtr 1,715.96 (+4.6%)

Profit after tax

Latest 156.37; Year ago 128.47 (+21.7%); Prev qtr 150.83 (+3.7%)

Period

Quarter ended 30.09.2026 (Unaudited)

The board of directors met on 05 November 2026 and approved the unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026. Separately, it considered and approved an investment into the formation of a new joint venture.

Standalone results (INR in lakhs)

• Revenue from operations for the quarter ended 30 September 2026: 1,465.96; the same line was 919.74 in the quarter ended 30 September 2025.
• Total revenue for the quarter: 1,514.25; total expenses 1,370.59.
• Profit before tax: 143.66; current tax 31.15 and deferred tax 1.36.
• Net profit after tax: 111.15, against 81.76 in the year-earlier quarter.
• Earnings per share (not annualised): basic 0.77, diluted 0.64.
• Half year: revenue from operations 2,883.78, total revenue 3,000.41, net profit after tax 217.59, basic EPS 1.51.
• The company reports a single business segment, Speciality & Fine Chemicals.

Consolidated results (INR in lakhs)

• Quarter: revenue from operations 1,772.02, total revenue 1,794.63, profit before tax 206.19.
• Net profit after tax for the quarter: 156.37, of which 135.12 is attributable to shareholders of the company and 21.25 to non-controlling interests.
• Half year: revenue from operations 3,446.90, total revenue 3,510.59, net profit after tax 307.21.
• EPS (not annualised): basic 0.93 and diluted 0.78 for the quarter; 1.84 and 1.54 for the half year.
• The group reports two segments, Speciality and Fine Chemicals and Logistics Services. It includes subsidiary Eikovivify Logistics Private Limited and associates Reflux Pharmaceuticals Private Limited and SSM Formulations Private Limited.

The joint venture

• Eiko Scientific Solutions LLP, a wholly owned subsidiary of the company, will invest in the formation of a new 50-50 joint venture private limited company with Oval Projects Engineering Limited.
• The proposed company is to carry on business in the name Oval Eiko Resources Private Limited.

Auditor's review

• P S V Jain & Associates issued limited review reports on both the standalone and the consolidated statements. A review gives moderate assurance and is not an audit opinion.
• Conclusion on both statements: nothing came to the auditor's attention that causes it to believe the statements contain a material misstatement or fail the required disclosures.
• For the consolidated statement, the auditor did not review the interim financial results of 2 associates; those results reflect total revenues of 1,525.22 lakh and net profit after tax of 18.76 lakh. The conclusion is not modified in respect of this matter.

Balance sheet and cash (standalone, INR in lakhs)

• Total assets: 8,239.37 as on 30 September 2026 against 8,279.17 as on 31 March 2026.
• Cash and cash equivalents: 307.95 against 1,355.16.
• Current borrowings: 79.53 against 167.45; non-current borrowings 136.00 as on 30 September 2026.
• Net cash used in operating activities for the half year ended 30 September 2026: 979.06.

What a retail investor can take away

• Two decisions came in one update: the quarterly and half-yearly numbers, and a move to set up a joint venture with an outside partner.
• The joint venture is described as being at formation stage — the update sets out the 50-50 structure and the proposed name, Oval Eiko Resources Private Limited.
• The auditor's review of both statements carries a clean conclusion, with the note that 2 associates' interim results were reviewed by other auditors.
• On the numbers, the quarter's revenue from operations and net profit after tax on a standalone basis are higher than the same quarter a year earlier, while cash and cash equivalents have come down from the 31 March 2026 level.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev